| Entries |
| Document | Title | Date |
|---|
| 20080242690 | Methods and Compositions for Promoting Bone and Joint Health - Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed. | 10-02-2008 |
| 20080280935 | Process to Prepare Camptothecin Derivatives - A process is provided for the preparation of camptothecin derivatives, such as irinotecan, in a one-pot operation. | 11-13-2008 |
| 20080318992 | METHOD OF USING A PKC INHIBITOR TO REVERSE PREFRONTAL CORTICAL DECLINES - Aging is associated with deficiencies in the prefrontal cortex, including working memory impairment, and compromised integrity of neuronal dendrites. The role of Protein Kinase C(PKC) in age-related prefrontal cortical impairments had not been previously determined. The inventors provides evidence that PKC activity is associated with prefrontal cortical dysfunction in aging. The inventors provide methods of reversing the effects of prefrontal cortical decline, improving cognition, and improving working memory in aged subjects by providing a phenanthridinium alkaloid or closely related compound to the subject. The inventors found chelerythrine reversed working memory impairments in aged rats and enhanced working memory in aged rhesus monkeys. Improvement correlated with age, with older monkeys demonstrating a greater degree of improvement following PKC inhibition. The inventors findings indicate that PKC is dysregulated in aged subjects and that PKC inhibitors may be used to treatment improve cognition in the elderly. | 12-25-2008 |
| 20090076050 | SYNERGISTIC TUMOR-KILLING EFFECT OF RADIATION AND BERBERINE COMBINED TREATMENT IN LUNG CANCER - A method for treating a subject suffering cancer, comprising administering an effective amount of berberine or its acid or ester derivates to the subject in need of such treatment, and radiating the cancer of the subject. | 03-19-2009 |
| 20090176816 | Drug composition for treating 2 type diabetes and diabetic chronicity complications - A drug composition for treating type 2 diabetes and diabetic chronicity complications is disclosed. The composition is composed of mangiferin and berberine in a certain ratio. The composition has a preferable hypoglycemic and hypolipidemic effect compared with mangiferin and berberine which is used alone | 07-09-2009 |
| 20090258890 | TOPOISOMERASE-TARGETING AGENTS - The invention provides compounds of formula I or formula II: | 10-15-2009 |
| 20100069422 | METHODS AND COMPOSITIONS FOR PROMOTING BONE AND JOINT HEALTH - Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed. | 03-18-2010 |
| 20100076005 | ISOCARBOSTYRIL ALKALOID DERIVATIVES HAVING ANTI-PROLIFERATIVE AND ANTI-MIGRATORY ACTIVITIES - Isocarbostyril alkaloid derivatives having an anti-proliferative and anti-migratory activities are disclosed. In particular, compounds of formula (I) or (II), as well as stereoisomers, tautomers, racemates, prodrugs, metabolites thereof, pharmaceutically acceptable salt and/or solvate are encompassed which are useful in the treatment and prophylaxis of cancer. Methods of preparation are also disclosed. | 03-25-2010 |
| 20100113494 | 13,13a-Dihydroberberine Derivatives For Use In Pharmaceutical Compositions - The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance. | 05-06-2010 |
| 20100120810 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES - The present invention relates to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac GTPases (Rac1, Rac1b, Rac2 and/or Rac3). | 05-13-2010 |
| 20100204258 | METHODS AND COMPOSITIONS FOR MODULATING INSULIN SECRETION AND GLUCOSE METABOLISM - The present invention relates to methods and compositions for treating or ameliorating the effects of diabetes. In addition, the present invention relates to methods and compositions for treating or preventing hyperglycemia, as well as modulating monoamine levels, islet β-cell insulin secretion, insulin and/or glucagon levels in a patient. In certain preferred embodiments, such methods include administering to a patient an effective amount of a vesicular monoamine transporter type 2 (VMAT2) antagonist, such as tetrabenazine (TBZ), dihydrotetrabenazine (DTBZ), tetrahydroberberine (THB), reserpine, emetine, Compound 6, or enantiomers, optical isomers, diastereomers, N-oxides, crystalline forms, hydrates, metabolites or pharmaceutically acceptable salts thereof. | 08-12-2010 |
| 20100222376 | CHELERYTHRINE, ANALOGS THEREOF AND THEIR USE IN THE TREATMENT OF BIPOLAR DISORDER AND OTHER COGNITIVE DISORDERS - The present invention relates to the use of chelerythrine and chelerythrine analogs in pharmaceutical compositions for the treatment of prefrontal cortical cognitive disorders, including bipolar disorder, among others. | 09-02-2010 |
| 20110003840 | Pyridoindolobenzox-and thiazepine derivatives and uses thereof - The present invention discloses pyridoindolobenzox- and thiazepine compositions of Formula 1, wherein | 01-06-2011 |
| 20110086872 | Berberine as a selective lung cancer agent and other compositions and methods - Berberine or its salts or derivatives are identified as the active compound for selectively inhibiting lung cancer, potentially without toxic side effects. Berberine is preferably obtained by synthesis or partial synthesis, or is obtained from natural sources, such as | 04-14-2011 |
| 20110144143 | PHARMACEUTICAL COMPOSITION CONTAINING FERULIC ACID AND MATRINE COMPOUNDS, THE PREPARATION AND THE USE THEREOF - Preparation and usage of a pharmaceutical composition containing ferulic acid and matrine compounds are described. The ingredients ferulic acid and matrine compounds in this pharmaceutical composition have synergistic effects which can obviously improve the pharmacology effects of both the ferulic acid and matrine compounds. Moreover, the pharmaceutical composition can significantly increase the aqueous and fat solubility of the individual ingredients. | 06-16-2011 |
| 20110207760 | SN-38 COMPOSITIONS - In one aspect, the present invention is directed to a stable aqueous composition including (a) SN-38; (b) a sulfoalkyl derivative of a cyclodextrin; and (c) water; in which the concentration of SN-38 in the composition is at least about 0.13 mg/g of the composition. In another aspect, this invention is directed to a process for making the composition which process comprises mixing SN-38 and a sulfoalkyl derivative of a cyclodextrin in an aqueous medium wherein the water content of the mixture is less than about 60% by weight. | 08-25-2011 |
| 20120035203 | BUTACLAMOL FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. | 02-09-2012 |
| 20120101117 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER - The invention provides compounds of formula I: wherein A, B, X, and Y have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds, processes for preparing such compounds, and therapeutic methods for treating cancer and other topoisomerase mediated conditions. | 04-26-2012 |
| 20120165357 | Compositions Containing Berberine or Analogs Thereof for Treating Rosacea or Red Face Related Skin Disorders - The invention pertains to topical pharmaceutical formulations of berberine and its biologically equivalent analogues, such as palmatine and coptisine, for the treatment of rosacea and other red face-related skin disorders. The topical pharmaceutical formulations of this invention contain purified berberine as the primary active drug ingredient at concentrations higher than 0.1%. The invention also pertains to methods of treating rosacea and other red face related skin disorders, such as steroid-induced rosacea-like dermatitis, comprising the administration of topical pharmaceutical formulations that contain berberine or its biologically equivalent analogues, such as palmatine. | 06-28-2012 |
| 20120184576 | ANTIPSYCHOTIC AGENTS AND STANDARDIZED ANTIPSYCHOTIC FRACTIONS FROM RAUWOLFIA TETRAPHYLLA AND PROCESS OF THEIR ISOLATION - The present invention relates to bioactive extracts its fractions and isolation of compound from | 07-19-2012 |
| 20120283282 | Photoproducts of Tryptophan, Their Synthesis and Uses Thereof - We have found that exposure of an aqueous tryptophan solution to window sunlight results in the production of multiple tryptophan photoproducts that have the capability of activating the aryl hydrocarbon receptor and increasing the production of AhR target genes and proteins in hepatocytes. We have isolated three of those photoproducts not previously identified as AhR activators, their chemical identification and synthesis and the demonstration that all three have biologic activities as novel AhR activators. Further, one of the three is a completely novel, not previously described, chemical compound. | 11-08-2012 |
| 20130045987 | NOVEL METHODS OF USE OF TETRAHYDROBERBERINE (THB) - Tetrahydroberberine (THB), isolated from the Chinese herb “ | 02-21-2013 |
| 20130072513 | COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES - This invention relates to compositions and methods of combining berberine, artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses by administration of a therapeutically effective amount of the composition. | 03-21-2013 |
| 20130102625 | Artemisinin with Berberine Compositions and Methods of Making - An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for treatment and prevention of malaria, dengue fever, yellow fever, dysentery, Lyme disease, babesiosis, progressive multifocal leukoencephalopathy, | 04-25-2013 |
| 20130237556 | BERBERINE ALKALOID AS A MEDICAMENT FOR PREVENTION AND TREATMENT OF NEURAL DISEASE - The present invention is directed to method of preventing or treating neural disease or inhibiting accumulation of β-amyloid plaques in a subject by administering an effective dosage to the subject an agent (berberine) which inhibits the accumulation of β-amyloid- plaque, phospho-amyloid precursor protein (p-APP) and tau hyperphosphorylation in a mammalian brain. | 09-12-2013 |
| 20130237557 | TREATMENT - The present invention derives from the finding that increased levels of alpha 2a adrenergic receptors (ADRA2a) are associated with chronic liver disease and that by decreasing ADRA2a levels in vivo, a number of symptoms and consequences of chronic liver disease may be reduced. Accordingly, the invention provides ADRA2a antagonists for use in a method of treating an individual suffering from liver disease. | 09-12-2013 |
| 20130261142 | COMPOUNDS USED FOR TREATING CANCER AND THE USE THEREOF - The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate | 10-03-2013 |
| 20130281478 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION - The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell. | 10-24-2013 |
| 20130310411 | NOVEL ACRIDINE DERIVATIVES - The present invention relates to novel acridine derivatives of formula (I), or pharmaceutically acceptable salts thereof, which are inhibitors of the telomerase enzyme function. These compounds are useful for the treatment cellular proliferation disorders, such as cancer. | 11-21-2013 |
| 20130345249 | Formulations for the prevention and treatment of Wolbachia-related disease - The invention encompasses pharmaceutical formulations for the prevention and treatment of | 12-26-2013 |
| 20140011829 | Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease - The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual. | 01-09-2014 |
| 20140011830 | Artemisinin-Based Combination Therapy For Treating Parasitic Mediated Disease - The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy, known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. | 01-09-2014 |
| 20140018382 | Method for treament of neurologic dysfunction - A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. | 01-16-2014 |
| 20140088130 | HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on. | 03-27-2014 |
| 20140200234 | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS - The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization. | 07-17-2014 |
| 20140213604 | PROTEIN KINASE C AS A TARGET FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS - The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC inhibitor and a pharmaceutically acceptable carrier. | 07-31-2014 |
| 20140256761 | ENHANCED ARTEMISININ-BASED COMBINATION THERAPY FOR TREATING PARASITIC MEDIATED DISEASE - The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy (ACT), known as ActRx Tri-ACT Plus. The improved ACT therapy includes administering a combination of four drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. A fourth composition, an effective amount of primaquine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. | 09-11-2014 |
| 20140256762 | ARTEMISININ-BASED COMBINATION THERAPY FOR TREATING VIRAL MEDIATED DISEASE - The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual. | 09-11-2014 |
| 20140323511 | CHEMOTHERAPEUTIC FOR INDUCING AN MSH2 DEPENDENT APOPTOTIC PATHWAY - Active compounds include compounds of Formula I and Formula II are described: | 10-30-2014 |
| 20140350041 | Methods and Compositions for Treating a Disease Condition in a Subject - Methods for treating a disease condition in a subject are provided. The subject methods are characterizing by enhancing at least one symptom of the disease condition in a manner effective to cause the subject to mount a compensatory response effective to treat the disease condition. Also provided are compositions, kits and systems for practicing the subject methods. | 11-27-2014 |
| 20150031717 | Derivatives Of Protoberberine Biological Alkaloids And Use Of Same Inhibiting Ulcerative Colitis - Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same. | 01-29-2015 |
| 20150099772 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS - The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds, as well as intermediates used in the synthesis of substituted berbine compounds. Also provided are methods for using the substituted berbines to inhibit cancer cell growth. | 04-09-2015 |
| 20150119415 | METHODS AND COMPOSITIONS FOR IMPROVING GUT MICROBIOTA POPULATION - A method and a composition for improving gut micro biota structure, selectively increase a first gut microbiota population while simultaneously decrease a second gut micro biota population in a subject. The first gut micro biota population includes a short-chain fatty acid (SCFA)-producing bacterium and the second gut microbiota population includes an endotoxin-producing bacterium. | 04-30-2015 |
| 20150148364 | Artemisinin with Berberine Compositions and Methods of Making - An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for treatment and prevention of malaria, dengue fever, yellow fever, dysentery, Lyme disease, babesiosis, progressive multifocal leukoencephalopathy, | 05-28-2015 |
| 20150307508 | Application of an alkaloid derived from a Chinese herbal for treatment of cancer by inhibiting cholesterol synthesis and fatty acid oxidation - The present invention discloses a method of treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein. | 10-29-2015 |
| 20150320738 | BERBERINE-CONTAINING PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER STEM CELL GROWTH OR CARCINOMA METASTASIS AND APPLICATION THEREOF - A pharmaceutical composition for inhibiting cancer stem cells growth or carcinoma metastasis and an application thereof are disclosed. The pharmaceutical composition includes: a berberine compound; and a pharmaceutically acceptable carrier. The application is the use of the berberine compound in the manufacture of a medicament for the inhibition of cancer stem cell growth or carcinoma metastasis. | 11-12-2015 |
| 20160038477 | ANTIFUNGAL DRUGS - The present invention relates to the administration of compounds of formula (I) for the treatment and/or prevention of fungal infections in subjects in need thereof. The methods of the invention also relates to the administration of pharmaceutical compositions comprising compounds of formula (I) for the treatment and/or prevention of fungal infections in subjects in need thereof. Subjects suffering from fungal infection and immunocompromised subjects may particularly benefit from the methods and compositions of the invention. | 02-11-2016 |
| 20160082000 | COMPOSITIONS AND METHODS FOR TREATING CARDIOMETABOLIC DISEASES AND DISORDERS - Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and re lated medical uses are also described. | 03-24-2016 |
| 20160151338 | NUTRACEUTICAL COMPOSITION FOR THE TREATMENT OF EXCESS WEIGHT AND MODERATE HYPERCHOLESTEROLEMIA/DYSGLYCEMIA | 06-02-2016 |
| 20160193195 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | 07-07-2016 |
| 20160251368 | Novel 8-Oxoprotoberberine Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Therefor and Pharmaceutical Composition for Preventing or Treating Diseases Associated with Activity of NFAT5, Containing Same as Active Ingredient | 09-01-2016 |
